CRBPCorbus Pharmaceuticals Hold...

Nasdaq corbuspharma.com


$ 37.69 $ 0.21 (0.57 %)    

Wednesday, 01-May-2024 15:58:31 EDT
QQQ $ 422.58 $ 0.43 (0.1 %)
DIA $ 378.81 $ 0.76 (0.2 %)
SPY $ 500.35 $ -0.62 (-0.12 %)
TLT $ 88.50 $ 0.28 (0.32 %)
GLD $ 213.80 $ 1.92 (0.91 %)
$ 37.25
$ 36.62
$ 0.00 x 0
$ 0.00 x 0
$ 36.62 - $ 38.45
$ 3.03 - $ 49.87
133,290
na
161.2M
$ 1.16
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-12-2024 12-31-2023 10-K
2 11-07-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-07-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-09-2022 06-30-2022 10-Q
8 05-10-2022 03-31-2022 10-Q
9 03-08-2022 12-31-2021 10-K
10 11-12-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 03-15-2021 12-31-2020 10-K
14 11-09-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-11-2020 03-31-2020 10-Q
17 03-16-2020 12-31-2019 10-K
18 11-07-2019 09-30-2019 10-Q
19 08-08-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 03-12-2019 12-31-2018 10-K
22 11-08-2018 09-30-2018 10-Q
23 08-08-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-12-2018 12-31-2017 10-K
26 11-08-2017 09-30-2017 10-Q
27 08-09-2017 06-30-2017 10-Q
28 05-09-2017 03-31-2017 10-Q
29 03-08-2017 12-31-2016 10-K
30 11-10-2016 09-30-2016 10-Q
31 08-12-2016 06-30-2016 10-Q
32 05-13-2016 03-31-2016 10-Q
33 03-28-2016 12-31-2015 10-K
34 11-10-2015 09-30-2015 10-Q
35 08-13-2015 06-30-2015 10-Q
36 05-13-2015 03-31-2015 10-Q
37 02-10-2015 12-31-2014 10-K
38 11-13-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 corbus-announces-dosing-of-first-patient-in-us-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc

Study enrolling patients with metastatic urothelial cancer (mUC) and other Nectin-4 enriched tumors Emerging clinical profile f...

 oppenheimer-reiterates-outperform-on-corbus-pharmaceuticals-raises-price-target-to-58

Oppenheimer analyst Jeff Jones reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION